# MediciNova (MNOV) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MNOV
## Company Profile
- Ticker: MNOV
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 1.63 USD
- Market cap: 65956469.64 USD
- Last updated: 2026-09-04
## Business Overview
MediciNova is a biotechnology company with programs in inflammation, fibrosis, and neurological disease. Its story is built around repurposing and selective development rather than broad commercial scale.
## Why The Stock Is Moving

As of Sep 4, 2026, MNOV closed up 0.62% at $1.63. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, MediciNova sits in specialty biotechnology.

## Business Model

The company depends on clinical data, pipeline prioritization, and the chance to build value from a narrow set of programs.

## Landscape Position

MediciNova is a small-cap biotech name whose valuation depends on a few clinical catalysts.

## Future Catalysts

- MediciNova’s catalysts are its repurposed pipeline assets and any strategic update that clarifies which programs still matter. The company needs a clearer clinical path to regain attention.

## Recent News
- 2026-07-15 12:00 EST — [MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients](https://biopharmsignal.com/news/MNOV/medicinova-announces-patient-enrollment-milestone-achieved-in-seanobi-study-expa-14636d8a) — Source: MediciNova
- 2026-06-30 12:00 EST — [MediciNova CEO Provides Shareholder Update](https://biopharmsignal.com/news/MNOV/medicinova-ceo-provides-shareholder-update-9776ffac) — Source: MediciNova
- 2026-06-08 12:00 EST — [MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment](https://biopharmsignal.com/news/MNOV/medicinova-receives-notice-of-allowance-for-new-patent-covering-use-of-mn-166-in-761464fe) — Source: MediciNova
- 2026-05-26 23:00 EST — [MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)](https://biopharmsignal.com/news/MNOV/medicinova-announces-completion-of-last-patient-last-visit-in-the-mn-001-natg-202-clinical-trial-of-mn-001-tipelukast) — Source: MediciNova
- 2026-04-27 23:00 EST — [New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation](https://biopharmsignal.com/news/MNOV/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation) — Source: MediciNova